Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT03930953
Title A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Rituximab in Subjects With Relapsed or Refractory Non-hodgkin Lymphomas (R/R NHL)
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Celgene
Age Groups: adult | senior
Covered Countries USA | ITA | GBR | FRA | ESP | CAN | BEL | AUT

No variant requirements are available.